AC Immune (NASDAQ:ACIU) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of AC Immune (NASDAQ:ACIU) from a strong sell rating to a hold rating in a report published on Tuesday morning,Zacks.com reports.

Other analysts have also issued research reports about the stock. Wall Street Zen raised shares of AC Immune from a “hold” rating to a “buy” rating in a report on Tuesday, May 13th. BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Monday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, AC Immune has a consensus rating of “Moderate Buy” and an average price target of $10.00.

AC Immune Stock Up 9.1%

Shares of ACIU opened at $2.40 on Tuesday. The stock has a market cap of $240.98 million, a price-to-earnings ratio of -4.14 and a beta of 1.61. AC Immune has a 12 month low of $1.43 and a 12 month high of $3.98. The company has a 50-day moving average price of $2.16 and a two-hundred day moving average price of $1.98.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The business had revenue of $1.65 million for the quarter, compared to the consensus estimate of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%. Equities research analysts expect that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Two Sigma Advisers LP acquired a new stake in shares of AC Immune in the fourth quarter valued at approximately $36,000. Banque Cantonale Vaudoise acquired a new stake in shares of AC Immune in the first quarter valued at approximately $50,000. Sei Investments Co. acquired a new stake in shares of AC Immune in the second quarter valued at approximately $51,000. Jane Street Group LLC acquired a new stake in shares of AC Immune in the fourth quarter valued at approximately $66,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of AC Immune in the fourth quarter valued at approximately $118,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.